NasdaqGM - Nasdaq Real Time Price USD

Entrada Therapeutics, Inc. (TRDA)

9.09

-0.04

(-0.44%)

As of 3:56:46 PM EDT. Market Open.

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 hours ago

ETON

TRDA
-0.44%
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

TRDA
-0.44%

VRTX
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 21 days ago

TRDA
-0.44%
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment

The commencement of the randomised trial is scheduled for the third quarter of this year.

Clinical Trials Arena last month

TRDA
-0.44%
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom’s Medicines and Healthcare Products Regulator

GlobeNewswire last month

TRDA
-0.44%
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just released its latest annual results and things are looking bullish...

Simply Wall St. last month

TRDA
-0.44%
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

TRDA
-0.44%
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reporte

GlobeNewswire 2 months ago

TRDA
-0.44%
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

BLUE and GILD are in the spotlight this week on key updates.

Zacks 2 months ago

BMRN

GILD

TRDA
-0.44%
FDA removes clinical hold on Entrada’s Duchenne therapy

Entrada plans to initiate the Phase Ib study of ENTR-601-44 in the US in the first half of next year.

Clinical Trials Arena 2 months ago

TRDA
-0.44%

GLDAF
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF (IBB) ina

PREMIUM
MT Newswires 2 months ago

TRDA
-0.44%

IVVD

SMMT
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) --

GlobeNewswire 2 months ago

TRDA
-0.44%
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Entrada Therapeutics, Inc. (NASDAQ:TRDA) stands against the other cheap biotech stocks. Biotech Stocks Face Uncertainty Despite Interest Rate Cuts Biotechnology stocks are among the most volatile in the market […]

Insider Monkey 2 months ago

TRDA
-0.44%
Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment

The trial is designed to assess the tolerability, effectiveness and safety of the therapy.

Clinical Trials Arena 2 months ago

TRDA
-0.44%
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product

GlobeNewswire 2 months ago

TRDA
-0.44%
Azenta Announces the Election of Dipal Doshi to its Board of Directors

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. Mr. Doshi was nominated for election by the Board, together with nine returning directors, in December 2024.

PR Newswire 2 months ago

TRDA
-0.44%

AZTA
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

With its stock down 26% over the past month, it is easy to disregard Entrada Therapeutics (NASDAQ:TRDA). But if you pay...

Simply Wall St. 3 months ago

TRDA
-0.44%
Best Momentum Stocks to Buy for December 30th

CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.

Zacks 3 months ago

TRDA
-0.44%
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET). A live webcast will b

GlobeNewswire 4 months ago

TRDA
-0.44%
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating

Roth MKM last night initiated coverage of Entrada Therapeutics (TRDA) with a Buy rating and $29 price target Entrada is an early-stage biopharma that seeks to solve a key bottleneck, which is effectively delivering oligo drugs into hard-to-target regions to treat diseases driven by genetic mutations, such as Duchenne muscular dystrophy and myotonic dystrophy, the analyst tells investors in a research note. The firm views the company as an “overlooked neuromuscular innovator” and says the ENTR-60

TipRanks 4 months ago

TRDA
-0.44%

Performance Overview

Return	TRDA	S&P 500 (^GSPC)
YTD	-47.43%	-4.64%
1-Year	-31.40%	+11.76%
3-Year	+52.01%	+35.74%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Entrada Therapeutics, Inc. (TRDA)

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

FDA removes clinical hold on Entrada’s Duchenne therapy

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now

Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Best Momentum Stocks to Buy for December 30th

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating

Performance Overview